Here, treatment application of NCTD significantly arrested NSCLC progression in dose- and time-dependent manners via dose-dependent repression of activities of UBE2C and depression of autophagy genes in lung cancer cells (Figs. 6a−k, 7a−h; Supplementary Figure S2 and S3). This evidence concerns the gene UBE2C and lung carcinoma.